{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:25:14Z","timestamp":1783103114668,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Jiangsu Provincial Key Discipline and Laboratory Construction Funds of Urology","award":["2023YXZDXK02"],"award-info":[{"award-number":["2023YXZDXK02"]}]},{"name":"the National Clinical Key Discipline Construction Funds","award":["CZXM-ZK-47"],"award-info":[{"award-number":["CZXM-ZK-47"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05256-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:19:05Z","timestamp":1783055945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer"],"prefix":"10.1007","author":[{"given":"Yali","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baotai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"5256_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871","author":"RL Siegel","year":"2025","unstructured":"Siegel RL et al (2025) Cancer statistics, 2025. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"5256_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N et al (2022) Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol 5(6):628\u2013639","journal-title":"Eur Urol Oncol"},{"key":"5256_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043720","author":"F Sanguedolce","year":"2023","unstructured":"Sanguedolce F et al (2023) HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24043720","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5256_CR4","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L et al (2023) HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population. Oncologist 28(8):e617\u2013e624","journal-title":"Oncologist"},{"issue":"1","key":"5256_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01211-1","volume":"10","author":"X Guo","year":"2025","unstructured":"Guo X et al (2025) Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study. NPJ Precis Oncol 10(1):11. https:\/\/doi.org\/10.1038\/s41698-025-01211-1","journal-title":"NPJ Precis Oncol"},{"issue":"4_suppl","key":"5256_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2024.42.4_suppl.631","volume":"42","author":"C Li","year":"2024","unstructured":"Li C, Zhu J, Yu W (2024) Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer. J Clin Oncol 42(4_suppl):631\u2013631","journal-title":"J Clin Oncol"},{"issue":"12","key":"5256_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X et al (2024) Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol 42(12):1391\u20131402","journal-title":"J Clin Oncol"},{"key":"5256_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116060","volume":"169","author":"Y Jiang","year":"2025","unstructured":"Jiang Y et al (2025) First-line therapies analysis in advanced\/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq. Int Immunopharmacol 169:116060","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"5256_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","volume":"8","author":"F Miglietta","year":"2022","unstructured":"Miglietta F et al (2022) HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 8(1):66","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"5256_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bju.14366","volume":"122","author":"N Gandhi","year":"2018","unstructured":"Gandhi N et al (2018) Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int 122(5):744\u2013753","journal-title":"BJU Int"},{"key":"5256_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29342","author":"R Yu","year":"2024","unstructured":"Yu R et al (2024) MRI-based machine learning radiomics for preoperative assessment of human epidermal growth factor receptor 2 status in urothelial bladder carcinoma. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.29342","journal-title":"J Magn Reson Imaging"},{"key":"5256_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04378-6","author":"L Kong","year":"2024","unstructured":"Kong L et al (2024) Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study. Abdom Radiol. https:\/\/doi.org\/10.1007\/s00261-024-04378-6","journal-title":"Abdom Radiol"},{"issue":"3","key":"5256_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V et al (2018) Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 74(3):294\u2013306","journal-title":"Eur Urol"},{"issue":"1","key":"5256_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40644-021-00433-3","volume":"21","author":"Z Zheng","year":"2021","unstructured":"Zheng Z et al (2021) Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer. Cancer Imaging 21(1):65","journal-title":"Cancer Imaging"},{"issue":"1","key":"5256_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12885-025-13549-7","volume":"25","author":"H Xie","year":"2025","unstructured":"Xie H et al (2025) Revolutionizing HER-2 assessment: multidimensional radiomics in breast cancer diagnosis. BMC Cancer 25(1):265","journal-title":"BMC Cancer"},{"key":"5256_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241293699","volume":"31","author":"L Shen","year":"2024","unstructured":"Shen L et al (2024) HER2 in gastric cancer: a comprehensive analysis combining meta-analysis and DCE-MRI radiomics. Cancer Control 31:10732748241293699","journal-title":"Cancer Control"},{"key":"5256_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04767-x","author":"C Luo","year":"2025","unstructured":"Luo C et al (2025) Noninvasive identification of HER2 status by integrating multiparametric MRI-based radiomics model with the vesical imaging-reporting and data system (VI-RADS) score in bladder urothelial carcinoma. Abdom Radiol. https:\/\/doi.org\/10.1007\/s00261-024-04767-x","journal-title":"Abdom Radiol"},{"issue":"1","key":"5256_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.acra.2019.07.030","volume":"27","author":"SM Borstelmann","year":"2020","unstructured":"Borstelmann SM (2020) Machine learning principles for radiology investigators. Acad Radiol 27(1):13\u201325","journal-title":"Acad Radiol"},{"issue":"1","key":"5256_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12575-025-00261-w","volume":"27","author":"Y Chen","year":"2025","unstructured":"Chen Y et al (2025) Impact of HER2 expression on the prognosis of muscle-invasive bladder cancer patients treated with bladder-preservation comprehensive therapy. Biol Proced Online 27(1):2","journal-title":"Biol Proced Online"},{"issue":"3","key":"5256_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","volume":"75","author":"TZ Tan","year":"2019","unstructured":"Tan TZ et al (2019) Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol 75(3):423\u2013432","journal-title":"Eur Urol"},{"issue":"1","key":"5256_CR21","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.clgc.2014.07.010","volume":"13","author":"SZ Millis","year":"2015","unstructured":"Millis SZ et al (2015) Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer 13(1):e37-49","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"5256_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.56434\/j.arch.esp.urol.20247701.11","volume":"77","author":"Q Li","year":"2024","unstructured":"Li Q et al (2024) HER2 affects the biological behaviours of bladder cancer cells and is closely associated with the progression and prognosis of bladder cancer. Arch Esp Urol 77(1):79\u201391","journal-title":"Arch Esp Urol"},{"key":"5256_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1243118","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S et al (2023) The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study. Front Oncol 13:1243118","journal-title":"Front Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05256-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:03:57Z","timestamp":1783101837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05256-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":23,"alternative-id":["5256"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05256-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Zhongda Hospital, Southeast University (Nanjing, China; Approval No. 2024ZDSYLL061-P01). Each participant signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}